Abstract
Use of HIV prevention methods may vary for women by types of sexual partners. In a microbicide safety and effectiveness trial (HPTN 035) differences in adherence to a microbicide study gel were compared between women with new versus ongoing partnerships over time. 1,757 women in the three HPTN 035 trial’s arms completed the Follow-up Partner Status (FPS) questionnaire at their last study visit. Women married at baseline were asked if they had the same husband, new husband or new partner. Unmarried women were asked if they had changed partners or married. Self-reported gel adherence during the last sex act was compared at each quarterly visit between women with ongoing versus new partners. High gel adherence was compared with low gel adherence (85–100 vs. <85 % of last vaginal sex acts reported with gel use, respectively) in multivariable models to assess associations with partner change. Overall 7 % of women (n = 123) reported a new partner and 41 % (51) of those reported a new husband. Median gel adherence was reported to be 100 % in women with ongoing partners and 75 % for women with new partners (p < 0.001). In women reporting no gel use in their last sex act, only 12.5 % of the women with a new partner and none of those with an ongoing partner reported using condoms (p < 0.001). Fewer women with new partners reported using both the gel and condom during the last sex act as compared to women with ongoing partners (median 50 vs. 71.4 %, p < 0.001). After adjusting for age, site, education level, and sexual frequency, women with ongoing partners were more likely to report high gel adherence than those with new partners (AOR 2.5, 95 % CI 1.6, 3.9). This pattern persisted when gel use over time was compared between women with new versus ongoing partners. In the HPTN 035 trial, women with new partners had higher HIV incidence and reported less gel use and higher condom use. Specific counseling and support are needed to help women use potential HIV prevention methods, including microbicides, when they are changing partners.
Similar content being viewed by others
References
Woodsong C, Alleman P, Musara P, et al. Preventive misconception as a motivation for participation and adherence in microbicide trials: evidence from female participants and male partners in Malawi and Zimbabwe. AIDS Behav. 2012;16(3):785–90.
Karim QA, Baxter C, Karim SA. Topical microbicides—what’s new? J Acquir Immune Defic Syndr. 2013;63(Suppl 2):S144–9.
Baeten J, Donnell D, Ndase P, et al. ARV PrEP for HIV-1 prevention among heterosexual men and women. . 19th Conference on Retroviruses and Opportunistic Infections (CROI). Seattle 2012.
Van Damme L, CorneliA, Ahmed K, et al. The FEM-PrEP trial of emtricitabine/tenofovir disoproxil fumarate (Truvada) among African women. Paper presented at: Conference on Retroviruses and Opportunistic Infections (CROI); 5–8 March, Seattle 2012.
Montgomery CM, Lees S, Stadler J, et al. The role of partnership dynamics in determining the acceptability of condoms and microbicides. AIDS Care. 2008;20(6):733–40.
Mah TL, Halperin DT. Concurrent sexual partnerships and the HIV epidemics in Africa: evidence to move forward. AIDS Behav. 2010;14(1):11–6 (dicussion 34–17).
Sawers L, Stillwaggon E. Concurrent sexual partnerships do not explain the HIV epidemics in Africa: a systematic review of the evidence. J Int AIDS Soc. 2010;13:34.
Mah TL, Maughan-Brown B. Social and cultural contexts of concurrency in a township in Cape Town, South Africa. Cult Health Sex. 2013;15(2):135–47.
Onoya D, Reddy P, Sifunda S, et al. Transactional sexual relationships, sexually transmitted infection risk, and condom use among young Black Women in peri-urban areas of the Western Cape Province of South Africa. Women’s health issues : official publication of the Jacobs Institute of. Women’s Health. May-Jun. 2012;22(3):e277–82.
Wyrod R, Fritz K, Woelk G, et al. Beyond sugar daddies: intergenerational sex and AIDS in urban Zimbabwe. AIDS Behav. 2011;15(6):1275–82.
Zembe YZ, Townsend L, Thorson A, Ekstrom AM. “Money talks, bullshit walks” interrogating notions of consumption and survival sex among young women engaging in transactional sex in post-apartheid South Africa: a qualitative enquiry. Glob Health. 2013;9:28.
Pettifor A, Macphail C, Anderson AD, Maman S. ‘If I buy the Kellogg’s then he should [buy] the milk’: young women’s perspectives on relationship dynamics, gender power and HIV risk in Johannesburg, South Africa. Cult Health Sex. 2012;14(5):477–90.
Montgomery ET, Chidanyika A, Chipato T, van der Straten A. Sharing the trousers: gender roles and relationships in an HIV-prevention trial in Zimbabwe. Cult Health Sex. 2012;14(7):795–810.
Abdool Karim SS, Richardson BA, Ramjee G, et al. Safety and effectiveness of BufferGel and 0.5 % PRO2000 gel for the prevention of HIV infection in women. AIDS. 2011;25(7):957–66.
Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168–74.
Marrazzo Jea. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE study (MTN 003). . 20th Conference on Retroviruses and Opportunistic Infections. Atlanta. 2013.
Minnis AM, Gandham S, Richardson BA, et al. Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women. AIDS Behav. 2013;17(2):737–47.
Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. New Engl J Med. 2010;363(27):2587–99.
Van Damme LCA, Ahmed K, Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, Malahleha M, Owino F, Manongi R, Onyango J, Temu L, Monedi MC, Mak’Oketch P, Makanda M, Reblin I, Makatu SE, Saylor L, Kiernan H, Kirkendale S, Wong C, Grant R, Kashuba A, Nanda K, Mandala J, Fransen K, Deese J, Crucitti T, Mastro TD, Taylor D, FEM-PrEP Study Group. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411–22.
Thirumurthy H, Siripong N, Vreeman RC, et al. Differences between self-reported and electronically monitored adherence among patients receiving antiretroviral therapy in a resource-limited setting. Aids. 2012;26(18):2399–403.
Warren SR, Raisch DW, Campbell HM, et al. Medication adherence assessment in a clinical trial with centralized follow-up and direct-to-patient drug shipments. Clin Trials. 2013;10(3):441–8.
Skoler-Karpoff S, Ramjee G, Ahmed K, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9654):1977–87.
Gorbach PM, Mensch BS, Husnik M, et al. Effect of computer-assisted interviewing on self-reported sexual behavior data in a microbicide clinical trial. AIDS Behav. 2013;17(2):790–800.
Acknowledgments
HPTN 035 was funded by the US National Institutes of Health and designed and implemented by the HPTN and the MTN. HPTN (U01AI46749) has been funded by the National Institute of Allergy and infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Drug Abuse, and National Institute of Mental Health (NIMH). MTN (U01AI068633) has been funded by NIAID, NICHD, and NIMH.
Author information
Authors and Affiliations
Corresponding author
Additional information
This study was conducted on behalf of HPTN 035 Protocol Team.
Rights and permissions
About this article
Cite this article
Gorbach, P.M., Kelly, C.W., Borgerding, J.A. et al. Effects of Partnership Change on Microbicide Gel Adherence in a Clinical Trial (HPTN 035). AIDS Behav 18, 855–861 (2014). https://doi.org/10.1007/s10461-013-0651-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10461-013-0651-5